Carnitine metabolism and carnitine deficiëncy Interaction of oxaliplatin chemotherapy with carnitine Chemotherapy induced peripheral neuropathy
Conditions
Interventions
No intervention/controls.
For measurements: drawing blood and collecting urine.
Sponsors
Máxima Medisch Centrum
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent 2. Age >18 years 3. Start treatment with oxaliplatin-based chemotherapy 4. Understanding the Dutch language
Exclusion criteria
Exclusion criteria: 1. Patients with known primary carnitine deficiency (congenital) 2. Patients on haemodialysis or peritoneal dialysis 3. Patients with epilepsy 4. Current treatment with valproic acid or zidovudine 5. Current use of carnitine supplements or use of carnitine supplements in the past 3 months 6. Pre-existent neuropathy or comorbid disorder causing neuropathy 7. Previous treatment with neurotoxic chemotherapy 8. Participation in an intervention study on CIPN (e.g. Frozen Gloves)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To evaluate the course of plasma- and urinary carnitine levels of all carnitine esters during the first cycle of treatment with oxaliplatin-based chemotherapy: Plasma and urinary concentrations of different carnitine-esters before, during and right after administration of oxaliplatin-based chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - To gain insight in patient factors such as lifestyle, diet and comorbidities that can influence baseline carnitine levels in cancer patients: Length and body weight, information about diet, nicotine- and alcohol consumption habits, comorbidities, type of cancer, cancer stage, chemotherapy regimen, history of chemotherapy use. | — |
Contacts
Public ContactL. Verdonschot
Outcome results
None listed